NCT00017199CompletedPhase 2
Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors
Ohio State University Comprehensive Cancer Center4 sites in 1 countryStarted: April 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Locations
- 4
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.
Detailed Description
OBJECTIVES:
- Determine the objective response rate of patients with metastatic neuroendocrine tumors treated with bortezomib.
- Determine the toxicity of this drug in this patient population.
- Determine the pharmacodynamics to correlate proteasome inhibition and efficacy of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.
PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 6 months.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Unknown
Phase 2
Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic NeuroblastomaNeuroblastomaNCT00024193Children's Cancer and Leukaemia Group
Completed
Phase 2
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic OsteosarcomaSarcomaNCT00005625Memorial Sloan Kettering Cancer Center
Completed
Phase 2
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast CancerBreast CancerNCT00003352NSABP Foundation Inc89
Completed
Phase 2
PS-341 in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00017329Memorial Sloan Kettering Cancer Center
Completed
Phase 1
PS-341 in Treating Patients With Advanced Solid Tumors or LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00004002NYU Langone Health